88% af de patienter, der blev behandlet med Pegasys oplevede uønskede hændelser sammenlignet med 53% af patienterne i sammenligningsgruppen behandlet med lamivudin.
Adverse events were experienced by 88% of Pegasys-treated patients as compared with 53% of patients in the lamivudine comparator group, while 6% of the Pegasys-treated and 4% of the lamivudine-treated patients experienced serious adverse events during the studies.